( for years. The need to take complement...)Though pharma growth slides, blockbusters reach new record

for years. The need to take complementary therapy in a number of classes of drugs as well as overall patient compliance has driven this trend.

Of real significance is the growth of blockbuster drugs. Remember that the definition of a blockbuster drug is annual sales of $1 billion or more. Some 20 years ago, there were less than a handful of blockbuster drugs. In 2004, there were a record......

Full article >>>
'"/>

Source:wistechnology.com By Michael Rosen 06/06/05


Page: 1 2 3
Related biology technology :

1. Though Weakening, Biotech IPO Market Still Viable, Burril & Co. Says
2. Though VC investing is down, reloading on new funds is rising
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Germantown drug company hires pharma veteran James Davidson as COO
5. New angel capital centered on GenTel agreement with big pharma
6. Big pharma seeks Wisconsin biotech partnerships
7. Doing the pharmaceutical tango
8. Chinese pharma-biotech dragon rears its head
9. Swiss biotech has quality of its big pharma, watch and chocolate industries
10. Third Wave receives FDA clearance of pharmacogenetic test
11. Line between big pharma, big biotech continues to blur